Investment, Funding & Disinvestments

Hellmann’s new Dubai South location responds directly to these mounting pressures by offering comprehensive capabilities designed to meet the sector’s most demanding standards.

The acquisition grants Biogen access to two already-marketed medications that generated USD689 million in sales last year.

The Raptor™ platform uses advanced genetic engineering tools to produce recombinant biologics inside eggs.

For MSD, this acquisition is part of a broader strategy to diversify its pipeline before its blockbuster immunotherapy Keytruda loses patent protection.

CVC first invested in Recordati in 2018, paying €3.03 billion (USD 3.5 billion) to acquire a 51.8% controlling stake.

SAT founder and Chief Medical Officer Dr Peter Zilla, alongside co-developers Dr Roman Gottardi and Dr Martin Czerny, confirmed that the results validate the device’s clinical value.

TB remains the deadliest infectious disease in the world, and a single untreated case can infect between 15 and 20 people within a year, making early diagnosis and uninterrupted treatment critical tools for containing any outbreak.

The acquisition signals Novartis’s confidence that Exl-111 can outperform this proven therapy by taking an entirely different approach.

The new facility adds to Tajmeel’s growing portfolio of over 30 specialized treatments spanning beauty, regenerative medicine, and surgical transformation.